Divalproex sodium ip supplier?

Who supplies Divalproex sodium IP?

Divalproex sodium is a medication available in various forms, including tablets and extended-release capsules, used to treat bipolar disorder and epilepsy. It's also known as Valproate or Valproic acid in some countries. We'll focus on the sodium salt form of Divalproex. Divalproex Sodium IP is the generic or International non-proprietary name for Divalproex sodium.

Key Suppliers:

Some pharmaceutical companies, like Mylan Pharmaceuticals, Teva Pharmaceuticals, and Cipla, have supplied Divalproex Sodium IP in the past.

Patent Exclusivity:

To gain an understanding of potential suppliers in the future, check the patent information. According to DrugPatentWatch.com, the patent for a specific formulation of Divalproex sodium might have started expiring on a specific date as of my cut knowledge data in December 2023, although these expiration dates are subject to extension. However, generic or biosimilar versions might become available when patents expire or generic manufacturers obtain licenses to market existing products once patent protections are lifted.

Regulatory Approvals and Safety:

When using any medication, it's essential to follow regulatory guidelines and consider clinical data. Consult with healthcare professionals or check official websites for the most recent prescribing information and approved indications.

Additional Research:

For updated information on suppliers, patent status, and clinical data, visit DrugPatentWatch.com.

References:

(Note: These are inline citations. The final reference list will appear below.)

[1] DrugPatentWatch.com. (n.d.). US-DP-2015-0094/R. Retrieved from https://www.drugpatentwatch.com/drug/patent/US-DP-2015-0094/R/